Clinical TrialCompleted

RTT Ketamine-Assisted Psychedelic Therapy: Indigenous Cohort Quality-Improvement Pilot (Roots to Thrive × Snuneymuxw First Nation, 2023)

Quality-improvement project with prospective data collection under Vancouver Island University (VIU) exemption (J Psychoactive Drugs 2023 Nov-Dec; Manson E, Ryding E, Taylor W, Peekeekoot G; PMID 37723666). Conducted by Roots to Thrive (RTT) in collaborative partnership with Snuneymuxw First Nation (formalised by MOU). Participants: n=10 Indigenous contributors — eight formed a discrete Indigenous small group within RTT cohort five; two Elders participated in mixed groups. No control arm, no randomisation. Intervention: RTT 12-week programme comprising weekly two-hour virtual sessions and three in-person group ketamine sits (IM, 1.0–1.5 mg/kg per sit) at weeks 4, 6 and 8, with 24–48-hour virtual integration sessions. CT.gov: 0 hits; PubMed DataBankList: empty; no formal clinical trial registration identified.

Target Enrollment
10 participants
Study Type
interventional
Design
Non-randomized

Study Details

  • Status
    Completed
  • Type
    interventional
  • Design
    Non-randomized
  • Target Enrollment10 participants
  • Timeline
    Start: 2022-01-01
    End: 2023-01-01

Related Publications

Indigenous Voices in Psychedelic Therapy: Experiential Learnings from a Community-Based Group Psychedelic Therapy Program

Published
Authors
Manson, E., Ryding, E., Taylor, W., Peekeekoot, G., Gloeckler, S. G., Allard, P., Johnny, C., Greenway, K. T., Dames, S.

Your Library